Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

VISTIN PHARMA Stock Went Up By Over 12% At Session Start On Friday

Loading stream...

(VIANEWS) - Shares of VISTIN PHARMA (Oslo Børs All-share Index_GI: VISTN.OL) jumped by a staggering 12.91% to kr18.80 at 10:41 EST on Friday, following the last session's upward trend. Oslo Børs All-share Index_GI is sliding 0.78% to kr1,405.92, after five consecutive sessions in a row of losses. This seems, as yet, a somewhat down trend trading session today.

About VISTIN PHARMA

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin hydrochloride APIs and direct compressive granulates for the pharmaceutical industry. The company was incorporated in 2015 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.96.

PE Ratio

VISTIN PHARMA has a trailing twelve months price to earnings ratio of 19.58. Meaning, the purchaser of the share is investing kr19.58 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for VISTIN PHARMA is 58691 which is 298.95% above its average volume of 14711.

Volatility

VISTIN PHARMA's last week, last month's, and last quarter's current intraday variation average was a negative 0.61%, a negative 0.13%, and a positive 2.18%.

VISTIN PHARMA's highest amplitude of average volatility was 2.76% (last week), 1.15% (last month), and 2.18% (last quarter).

More news about VISTIN PHARMA (VISTN.OL).